Th1 and Th2 profiles in patients with pancreatic cancer compared with chronic pancreatitis

Pancreas

Volumn 38, Issue 5, 2009, Pages 594-595

  Seicean, Andrada ^a   Popa, Daniel ^a   Mocan, Teodora ^a   Cristea, Victor ^a   Neagoe, Ioana ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 5;

CANCER PATIENT; CARCINOGENESIS; CELLULAR IMMUNITY; CHRONIC PANCREATITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; ENDOSCOPIC ECHOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; LETTER; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; TH1 CELL; TH2 CELL;

DIAGNOSIS, DIFFERENTIAL; ENDOSONOGRAPHY; HUMANS; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-2; INTERLEUKIN-4; INTERLEUKIN-5; INTERLEUKIN-6; INTERLEUKIN-8; INTERLEUKINS; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; PROSPECTIVE STUDIES; TH1 CELLS; TH2 CELLS;

EID: 67651113802     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31819313d0     Document Type: Letter

References (10)

1. Noh KW, Pungpapong S, Wallace MB, et al. Do cytokine concentrations in pancreatic juice predict the presence of pancreatic diseases? Clin Gastroenterol Hepatol. 2006;4(6):782-789.
2. Talar-Wojnarowska R, Gasiorowska A, Smolarz B, et al. Clinical significance of interleukin-6 (Il-6) gene polymorphism and Il-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis. Dig Dis Sci. 2008 Jul 26. [Epub ahead of print]
3. Okada S, Okusaka T, Ishii H, et al. Elevated serum interleukin-6 levels in patients with pancreatic cancer. Jpn J Clin Oncol. 1998;28(1):12-15. (Pubitemid 128527476)
4. Shimamura T, Royal RE, Kioi M, et al. Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma. Cancer Res. 2007;67(20):9903-9912. (Pubitemid 47621239)
5. Shchors K, Shchors E, Rostker F, et al. The myc-dependent angiogenic switch in tumors is mediated by interleukin 1A. Genes Develop. 2006;20(18):2527-2538. (Pubitemid 44396838)
6. Greco E, Basso D, Fogar P, et al. Pancreatic cancer cells invasiveness is mainly affected by interleukin-1beta not by transforming growth factor-beta1. Int J Biol Markers. 2005;20(4): 235-241. (Pubitemid 43103619)
7. Aoki H, Ohnishi H, Hama K, et al. Cyclooxygenase-2 is required for activated pancreatic stellate cells to respond to proinflammatory cytokines Am J Physiol Cell Physiol. 2007;292(1):C259-C268.
8. Angst E, Reber HA, Hines OJ, et al. Mononuclear cellYderived interleukin-1 beta confers chemoresistance in pancreatic cancer cells by upregulation of cyclooxygenase-2. Surgery. 2008; 144(1):57-65.
9. Ito Y, Aiura K, Ueda M, et al. Establishment of combined immuno-chemotherapy with systemically administered gemcitabine and intra-portal administration of interleukine-2 in murine models of liver metastasis in pancreatic cancer. Int J Oncol. 2008;33(1):49-58.
10. Ebrahimi B, Tucker SL, Li D, et al. Cytokines in pancreatic carcinoma. Cancer. 2004;101(12):2727-2736.